Myasthenia Gravis

Myasthenia gravis (MG) is a rare chronic autoimmune disease of the neuromuscular junction characterized by a bimodal age distribution and complex interactions between genetic predisposition and environmental triggers. While historically considered a disease of the young, recent temporal trends indicate a significant rise in the incidence and prevalence of the condition among the elderly ^[2].

Incidence and Prevalence

The global epidemiology of MG is shifting, with an increasing burden in the very old (defined as age >65 years) ^[2]. In women, the onset age distribution frequently peaks within the reproductive age range, which complicates clinical management during pregnancy and the postpartum period ^[1]. In contrast, childhood-onset myasthenia gravis (CMG) remains rare, though its incidence is reportedly increasing annually in certain regions, such as China, where it accounts for 10.3% to 12.6% of new cases ^[17]D. CMG typically exhibits a single peak at ages 1–3 years ^[17]D.

Serological status also varies by clinical phenotype. In patients with ocular myasthenia gravis (OMG), approximately 45.9% are positive for acetylcholine receptor antibodies (AChR-Ab+), while the remainder are seronegative ^[8]. The presence of these antibodies in OMG is a known risk factor for progression to generalized myasthenia gravis (gMG) ^[8].

Demographic Distribution

MG exhibits a distinct sex-based predilection that varies by age of onset:

• Early-Onset MG: Predominantly affects women, particularly those in their 20s and 30s ^[1].
• Late-Onset MG (LOMG): Defined as onset after age 50 or 65, this group shows an increasing incidence, likely due to unknown environmental factors and improved diagnostic recognition in the elderly ^[2][10].
• Childhood-Onset MG: In large cohorts, the male-to-female ratio is approximately 1:1.4, with a median onset age of 5 years ^[17]D.

Risk Factors and Triggers

Metabolic and Lifestyle Factors

Obesity has emerged as a significant risk factor for the development of MG. A nationwide cohort study found that individuals with a BMI ≥ 30.0 (Obese Class II) have a significantly higher risk of newly diagnosed MG (HR 1.33) compared to those with a normal BMI ^[13]. This association is thought to be mediated by the pro-inflammatory environment induced by excess adipose tissue ^[13].

Pharmacological Triggers

Several medication classes are associated with the induction or exacerbation of MG:

• Statins : Multinational real-world data suggest a potential risk of new-onset MG following the initiation of statin therapy ^[15]C.
• Immune Checkpoint Inhibitors (ICIs): These anti-tumor agents can induce neurotoxicity as an immune-related adverse event (irAE). Patients with preexisting MG or thymoma are at particularly high risk for severe flares when treated with ICIs ^[18]D[21]D.

Infectious Triggers

Infections are the most common triggers for both the initial onset and subsequent exacerbations of MG. In childhood-onset cases, the common cold is the most prevalent trigger ^[17]D. More recently, COVID-19 and Long COVID have been identified as independent predictors of MG exacerbation ^[3][9]. Long COVID, in particular, serves as a risk factor for increased disease severity and mortality in MG patients ^[9].

Comorbidities and Associated Risks

Patients with MG have a higher prevalence of several comorbidities compared to the general population. Circulatory diseases, particularly hypertension (13–24%), are frequent before diagnosis ^[24]D. Post-diagnosis, patients often develop anemia and osteoporosis, likely secondary to long-term immunosuppressive therapy ^[24]D.

There is also a documented increase in the prevalence of extrathymic neoplasms in MG patients (HR 1.34) ^[11]. While thymectomy is a standard treatment for MG, its long-term impact on the risk of developing other cancers or autoimmune diseases remains a subject of clinical debate ^[23]D. Furthermore, Mendelian randomization studies suggest that MG may have a causal influence on the risk of neurodegenerative disorders, including Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) ^[7].

Risk Factor Summary Table

Core clinical phenotype

Myasthenia gravis (MG) is a chronic autoimmune disorder of the postsynaptic neuromuscular junction characterized clinically by fluctuating, fatigable skeletal-muscle weakness. The contemporary treatment literature distinguishes ocular MG from generalized MG (gMG), in which weakness extends beyond the extraocular muscles and may impair bulbar, respiratory, axial, or limb function. ^{[100][101][141]} gMG is associated with substantial functional burden, impaired health-related quality of life, emergency-care use, and hospital utilization. ^[100][116] Symptoms may vary over time, and sustained control is therefore a clinically important outcome rather than a single cross-sectional response. ^[102]

Ocular manifestations include ptosis and diplopia, whereas generalized disease may involve facial, bulbar, neck, respiratory, trunk, and limb muscles. Real-world treatment analyses specifically evaluated improvement across ocular, bulbar, limb, and trunk domains, supporting the importance of documenting the distribution of weakness rather than relying only on a composite score. ^[122] Bulbar or respiratory involvement is particularly clinically consequential because uncontrolled gMG may lead to exacerbations requiring rescue therapy and, in severe cases, hospitalization. ^[137][116]

Immunologic and serologic variants

The major clinically studied serologic subgroups are acetylcholine-receptor-antibody-positive (AChR-Ab+), muscle-specific-kinase-antibody-positive (MuSK-Ab+), and lipoprotein-receptor-related-protein-4-antibody-positive (LRP4-Ab+) disease. ^[100] Complement-mediated injury is especially relevant to AChR-Ab+ gMG, which is the population targeted in pivotal trials of C5 inhibitors such as gefurulimab and included in comparative analyses of ravulizumab and zilucoplan. ^{[138][99][142]} FcRn-directed therapies, including efgartigimod, nipocalimab, and rozanolixizumab, reduce pathogenic IgG and have been studied across seropositive gMG populations, although the strongest pivotal evidence for efgartigimod concerns AChR-Ab+ disease. ^{[101][100][102][144]C}

Seronegative MG (SNMG) refers to patients with clinical and electrophysiological evidence of a postsynaptic neuromuscular-junction disorder but without detectable antibodies against currently recognized MG targets. ^[141] In a systematic review of 31 studies involving 712 patients, SNMG cohorts were predominantly female (473/712; 67%) and had a mean age at onset of 42 years; isolated ocular symptoms were reported as a characteristic presentation in the included literature. ^[141] Because SNMG is defined partly by the limitations of available antibody assays, diagnosis in reported cohorts relied on combinations of clinical findings, electrophysiology, pharmacological testing, and treatment response. ^[141] These methodological differences limit direct comparison of SNMG outcomes between studies. ^[141]

Clinical severity and response variants

Disease severity is commonly operationalized with the Myasthenia Gravis Foundation of America (MGFA) classification and quantified with MG-ADL and QMG scores. The PREVAIL trial enrolled adults with AChR-Ab+ gMG classified as MGFA II through IV, illustrating the clinically relevant spectrum from mild generalized weakness to more substantial disease. ^[138] Treatment studies define meaningful improvement using score thresholds rather than antibody reduction alone; examples include MG-ADL improvement of ≥2 or ≥3 points and QMG improvement of ≥3 or ≥4 points, with sustained responses assessed over 24 weeks in the nipocalimab program. ^[102]

A clinically useful response variant is minimal symptom expression (MSE), defined in one real-world efgartigimod study as an MG-ADL score of 0 or 1 within 4 weeks of treatment initiation and sustained for at least 4 consecutive weeks. ^[143] Predictors of MSE were investigated in 119 AChR-Ab+ patients, but the resulting nomogram is retrospective and should not be treated as a universal prognostic rule. ^[143] Other real-world data found improvement in multiple functional domains, reductions in MG-ADL and QMG scores, IgG reduction, and a steroid-sparing effect after at least two efgartigimod cycles; outcomes were also examined according to thymic status and background immunotherapy. ^[122]

Exacerbation-prone, refractory, and treatment-fluctuating disease

Uncontrolled moderate-to-severe gMG may be exacerbation-prone and require rescue therapy, including intravenous immunoglobulin or plasma exchange-based approaches. ^[137] Long-term Japanese post-marketing surveillance evaluated IVIg-treated gMG over 2 years, using retreatment with IVIg, intravenous methylprednisolone, plasmapheresis, or thymectomy because of progression or relapse as a clinically relevant endpoint. ^[95] Preoperative generalized disease is another important variant: in a retrospective cohort of 78 patients undergoing thymectomy, efgartigimod or lymphoplasmapheresis was compared with oral immunosuppression as rapid antibody-clearing preparation, with postoperative QMG, exacerbation, and postoperative myasthenic-crisis outcomes assessed. ^[94]

Complex gMG may be refractory, involve contraindications or intolerance to immunosuppressants, or be highly active. In a small series of 8 AChR-Ab+ patients, relapse after intermittent rozanolixizumab led to weekly or fortnightly non-cyclic administration, reflecting a possible wearing-off or fluctuation phenotype; this evidence is observational and preliminary. ^[144]C Early B-cell-directed treatment has likewise been explored in non-thymomatous, immunosuppression-naïve AChR-Ab+ gMG within 12 months of generalization, using a single low-dose rituximab infusion in a retrospective series of 17 patients. ^[114]C

Treatment-relevant clinical distinctions

Clinical selection increasingly depends on antibody status, distribution and severity of weakness, prior response, durability, rescue-therapy requirement, comorbidity, and administration feasibility. ^{[99][101][102]} Inebilizumab trials specifically examined exacerbations and rescue-therapy use in adults with generalized disease, whereas gefurulimab evidence is restricted to AChR-Ab+ gMG. ^[137][138] Nipocalimab studies included seropositive AChR-, MuSK-, or LRP4-antibody-associated gMG and assessed health-related quality of life, fatigue, sustained disease control, and hospital-resource outcomes. ^{[100][102][116]}

Safety interpretation must remain phenotype- and therapy-specific. FcRn blockade can affect IgG-mediated immune protection; post hoc analyses evaluated vaccine antibody responses and viral-infection-related immunity during nipocalimab treatment. ^[140] Observational data on C5 inhibitors found improved survival but also reported increased cardiovascular risk, including cardiovascular and thromboembolic outcomes, emphasizing the need to distinguish therapeutic benefit from treatment-associated risk. ^[124]C Eculizumab response may be inadequate in some patients, prompting investigation of exposure targets and dose-interval adjustment, although available concentration estimates remain uncertain. ^[110] A prospective cohort also examined sequential eculizumab after poor early response to efgartigimod, but this evidence is low-level and should not be generalized. ^[111]C Finally, device usability studies in gMG found that 94% successfully completed simulated use with autoinjector or prefilled-syringe systems without training, supporting administration feasibility but not clinical efficacy. ^[139]

Practical classification

For clinical documentation, record whether disease is ocular or generalized; the dominant affected domains; MGFA class; AChR, MuSK, LRP4, or seronegative status; exacerbation or rescue-therapy history; thymic status; treatment responsiveness and durability; and clinically important comorbidities. This structured description captures the major variants represented in current evidence and helps prevent inappropriate extrapolation across antibody-defined or severity-defined populations. ^{[100][101][102][141]}

Recognition and escalation

Myasthenic crisis (MC) is a life-threatening complication characterized by severe generalized weakness with bulbar and/or respiratory involvement and may require intensive-care monitoring and mechanical ventilation ^{[49][55][46]D}. Impending myasthenic crisis (IMC) has been operationalized as rapidly progressive bulbar or respiratory symptoms over ≤2 weeks, with at least one of the following: MGFA grade IVb, a QMG bulbar subscore of 3, a respiratory subscore of 2, or a combined bulbar–respiratory subscore of ≥4 ^[49]. Patients meeting these thresholds should undergo urgent respiratory and bulbar assessment, close observation for aspiration or ventilatory failure, and early escalation to rescue immunotherapy; the cited studies do not establish a single universally superior rescue strategy ^[49][89][97].

Management should be coordinated in an intensive-care or intermediate-care setting when respiratory or bulbar weakness is progressing, with serial clinical assessment and ventilatory support when required ^[46]D. Standard rescue options include IVIg, plasma exchange (PLEX), immunoadsorption, and high-dose corticosteroids ^[46]D. A systematic review and meta-analysis of randomized trials across autoimmune neurological disorders compared TPE with IVIg for effectiveness, safety, and economic outcomes, but the supplied abstract does not provide MG-specific effect estimates; therefore, treatment selection should remain individualized according to severity, vascular access, infection and thrombosis risk, renal or cardiac status, availability, and prior response ^[89].

IVIg, plasma exchange, and FcRn-directed therapy

IVIg and PLEX are established rapid therapies for severe exacerbation or crisis, with broadly comparable efficacy reported in the clinical literature summarized by the IVIg non-response study ^[97]. In patients receiving IVIg for a first crisis or severe exacerbation, non-response is clinically important because delayed recognition may permit respiratory or bulbar deterioration; the cited cohort specifically sought predictors of poor response, although the supplied abstract does not report the predictors ^[97]. Long-term Japanese post-marketing surveillance followed patients with generalized MG who received IVIg and evaluated time to retreatment with IVIg, intravenous methylprednisolone, plasmapheresis, or thymectomy because of progression or relapse, together with safety and cost-effectiveness over 2 years ^[95]. These data support IVIg as a real-world treatment option but do not imply that repeated IVIg replaces maintenance immunotherapy ^[95].

Efgartigimod, an FcRn antagonist, has been studied as a rapid option in acute deterioration. In a randomized prospective comparison of 38 AChR-antibody-positive patients with IMC, participants received efgartigimod 10 mg/kg weekly for 4 weeks or IVIg; the study was designed to compare short-term efficacy and safety ^[49]. A multicenter real-world study treated 61 patients with acute exacerbation or worsening of generalized MG with weekly efgartigimod for 4 weeks, assessing MGFA post-intervention status, QMG, and MG-ADL from baseline through week 7 ^[30]. A prospective multicenter observational study also compared 3–5 sessions of double-filtration plasmapheresis with four weekly efgartigimod infusions, including outcomes immediately after treatment and 1 month later ^[98]. These studies support severity- and patient-specific selection, while the observational designs and incomplete comparative results in the supplied abstracts limit definitive ranking of the therapies ^[30][49][98].

Complement inhibition in refractory crisis

Complement C5 inhibition is an escalation strategy for selected AChR-antibody-positive patients with highly active or treatment-refractory generalized MG. In a multicenter retrospective analysis of 17 German cases, eculizumab or ravulizumab was administered in ICU or intermediate care for therapy-refractory MC or severe exacerbation, defined as MGFA IVb/V, after standard treatment ^[46]D. A separate emergency case series described 5 acute episodes in four AChR-antibody-positive patients treated with eculizumab for impending or manifest crisis without IVIg, PLEX, or FcRn inhibition during the preceding month ^[41]C. Retrospective real-world cohorts also evaluated eculizumab in highly active AChR-positive generalized MG, including thymoma-associated and late-onset subgroups, and reported clinical outcomes and safety ^[90]C[92]C. These data are encouraging but are not substitutes for airway management or standard rescue therapy, and their low-level evidence and small samples require specialist oversight ^{[41]C[46]D[90]C[92]C}.

Cardiopulmonary and postoperative complications

Takotsubo cardiomyopathy can occur during MG exacerbation or crisis and represents an important differential diagnosis when acute cardiac dysfunction, chest symptoms, hemodynamic instability, or unexplained respiratory deterioration develops ^[50]. A systematic review of case reports and series analyzed MG-associated Takotsubo cardiomyopathy by apical and non-apical subtype; because the evidence derives from case reports, clinicians should confirm cardiac involvement with appropriate cardiac evaluation while continuing to assess for neuromuscular respiratory failure ^[50].

Thymectomy requires perioperative optimization and postoperative surveillance. In thymoma-associated MG, a multicenter retrospective cohort of 347 patients evaluated whether longer preoperative immunotherapy reduced exacerbation within 1 year after surgery ^[93]. Another retrospective study of 78 generalized-MG patients compared oral immunosuppression with rapid antibody-clearance preparation using lymphoplasmapheresis or efgartigimod before thymectomy, assessing postoperative QMG, exacerbation, MG-ADL, operative outcomes, postoperative crisis, and cost ^[94]. A five-year Colombian cohort reported clinical outcomes after thymectomy, including complete stable remission, pharmacologic remission, and minimal manifestations ^[54]. During non-thoracic surgery, MG should be treated as a risk factor for postoperative respiratory and other complications: a propensity-matched national analysis evaluated index-hospitalization and 90-day outcomes after four common spine procedures in MG versus non-MG patients ^[91].

Medication-related and long-term complications

Immune checkpoint inhibitors can provoke immune-related adverse events and MG flares. In a retrospective cohort, six patients with preexisting MG and thymoma received checkpoint-inhibitor therapy and were compared with ten thymoma patients without MG; MG flares, irAEs, outcomes, AChR-antibody levels, and tumor features were reviewed ^[21]D. Such treatment therefore warrants multidisciplinary risk assessment and close neuromuscular monitoring ^[21]D.

After MC, follow-up should extend beyond hospital discharge. A prospective multicenter study of 277 patients with 282 crisis episodes reported in-hospital mortality and followed MGFA post-intervention status, mortality, and complications at 1, 2, 3, 6, and 12 months ^[55]. Population-based Korean data further evaluated long-term mortality in incident MG from 2005–2020 against age- and sex-matched controls and examined associated risk factors ^[96]. Dynamic AChR-antibody monitoring after minimal symptom expression was investigated as a predictor of exacerbation in derivation and validation cohorts, with exacerbation defined as an MG-ADL increase of ≥2 points ^[53]. Finally, double-seronegative MG remains incompletely characterized; a systematic review of case reports and case series summarized its clinical features, treatment, and outcomes, so complication planning should not rely solely on antibody status ^[33].

Overall outlook

Myasthenia gravis (MG) remains a chronic, fluctuating autoimmune neuromuscular disorder in which prognosis is determined by disease distribution, antibody subtype, age at onset, comorbidity burden, treatment response, and occurrence of myasthenic crisis. The supplied updated evidence focuses primarily on generalized MG (gMG), treatment response, sustained disease control, health-related quality of life (HRQoL), and treatment safety rather than untreated natural history. ^{[99][100][102][106]}

Health-related impairment remains clinically important. A systematic review and meta-analysis of EQ-5D studies found that adults with MG have measurable reductions in health utility and self-rated health, although estimates varied according to population, instrument, tariff, and study design; the review included 10 studies and used random-effects methods with subgroup and sensitivity analyses. ^[106] Fatigue is a major contributor to long-term disability and is distinct from fatigable weakness. In a prospective study of clinically stable patients, depressive symptoms—but not obstructive sleep-apnea severity—were associated with general fatigue. ^[112]

Sustained disease control and quality of life

Novel therapies can improve patient-reported outcomes in addition to examination-based measures. In the phase 3 Vivacity-MG3 study, seropositive adults with gMG received nipocalimab or placebo alongside standard-of-care therapy for 24 weeks; prespecified outcomes included MG-QoL15r, Neuro-QoL Fatigue, EQ-5D-5L, and patient global assessments of fatigue. ^[100] Post hoc Vivacity-MG3 analyses specifically evaluated whether nipocalimab produced sustained responses over the same 24-week period, using meaningful clinical improvement, substantial improvement, and other response categories for MG-ADL and QMG scores. ^[102]

Efgartigimod also demonstrated efficacy across clinically relevant subgroups in the AChR-antibody-positive ADAPT population. Participants received four once-weekly infusions per treatment cycle over 26 weeks, and subgroup analyses examined MG-ADL and QMG responder rates during cycles 1 and 2 together with treatment-emergent adverse events. ^[101] A Bayesian network meta-analysis of randomized trials sought to compare generalized-MG treatments while accounting for differences between trial populations; it searched major databases through 2 May 2025 and included prospective studies of adults reporting treatment differences in MG-ADL outcomes. ^[99]

Targeted therapies and longer-term treatment implications

Complement-directed treatment remains particularly relevant to antibody-positive gMG. The phase 3 NIMBLE trial evaluated cemdisiran, an siRNA targeting complement C5, as monotherapy and in combination with the C5 antibody pozelimab in adults with generalized MG who were anti-AChR- or anti-LRP4-antibody positive and had baseline MG-ADL scores of ≥6. ^[103] Vemircopan was evaluated as an oral, selective factor-D inhibitor intended to block alternative-pathway complement activation while preserving classical and lectin pathway activity; the randomized trial enrolled adults with AChR-antibody-positive gMG. ^[107]

Real-world evidence suggests potential benefit in difficult-to-treat populations, but it is less definitive than randomized evidence. A retrospective study evaluated eculizumab in refractory late-onset, AChR-antibody-positive gMG, a population described as having immunosenescence, comorbidity-related treatment limitations, and high crisis risk; outcomes included clinical response, safety, and HRQoL. ^[92]C A prospective cohort of patients with poor early response to one efgartigimod cycle examined subsequent eculizumab treatment, enrolling 18 inadequate responders from an initially followed group of 103 patients. ^[111]C These findings support consideration of sequential treatment strategies but do not establish comparative long-term superiority. ^[111]C

IVIg continues to have a role in generalized disease. Japanese post-marketing surveillance across 316 facilities assessed two-year effectiveness, safety, and cost-effectiveness after initial IVIg exposure; the primary outcome was time to retreatment with IVIg, intravenous methylprednisolone, plasmapheresis, or thymectomy because of progression or relapse. ^[95] For patients undergoing thymectomy, a retrospective study of 78 individuals compared conventional oral immunosuppression with rapid antibody-clearing preparation using lymphoplasmapheresis or efgartigimod, assessing postoperative QMG, exacerbations, MG-ADL, postoperative crisis, surgical outcomes, and costs. ^[94]

Steroid-sparing and investigational approaches

Early low-dose rituximab may improve disease control and reduce corticosteroid exposure in selected non-thymomatous, immunosuppression-naïve, AChR-antibody-positive gMG. A retrospective South Wales cohort treated patients within 12 months of generalization with a single 500-mg infusion and assessed MGFA class, ADL, rescue treatment, prednisolone dose, and adverse events through more than 12 months. ^[114]C A separate retrospective study developed and validated a predictive model for minimal symptom expression after rituximab in AChR-antibody-positive MG, reflecting heterogeneous treatment response. ^[115]

Lifestyle interventions may influence long-term functioning, but current evidence is preliminary. A randomized pilot study assigned 41 adults with generalized MG to a ketogenic diet or habitual diet for 12 weeks, evaluating MG-ADL, QMG, MGFA class, fatigue, HRQoL, patient-acceptable symptom state, and immunological markers. ^[104]C The DIG-MG randomized feasibility trial used digital monitoring followed by 12 weeks of physical-activity guidance, sleep-hygiene education, or observation, with fatigue and MG-ADL as principal outcomes. ^[105]C

CAR-based cellular therapy remains investigational. A systematic review and meta-analysis assessed clinical remission, medication-free remission, and adverse events across autoimmune diseases, while another systematic review included 32 studies and 124 patients, with MG among the principal diseases represented. ^[109][113] These data are largely derived from small studies, case reports, and early clinical investigations and should not yet be interpreted as establishing durable MG remission. ^[109][113]

Prognostic cautions

Treatment decisions should balance sustained symptom control against infection, infusion, immunosuppression, and disease-specific risks. Complement inhibition has established clinical utility but may increase susceptibility to meningococcal infection; alternative-pathway inhibition is being developed partly to preserve other complement-mediated immune responses. ^[107] Rare immune-checkpoint-inhibitor-associated MG–myositis–myocarditis overlap can be life-threatening; a case report described successful rescue with eculizumab in tislelizumab-related overlap syndrome with dual AChR and titin antibody positivity, but case-level evidence cannot define general prognosis. ^[108] Overall, newer therapies offer increasing opportunities for sustained functional and HRQoL improvement, while the durability of benefit, optimal sequencing, and likelihood of medication-free remission remain incompletely defined. ^{[99][100][102][103][106][109][111]C[113]}

Pregnancy and postpartum

Pregnancy-associated disease activity remains clinically important, but its effect on myasthenia gravis (MG) has historically been uncertain. A nationwide Swedish register-based cohort specifically assessed MG exacerbations during pregnancy and through 1 year postpartum, comparing hospital admissions with MG against the year before pregnancy; the study used singleton pregnancies recorded after MG diagnosis and Cox proportional-hazards modelling. ^[119] The supplied abstract does not report the numerical hazard estimates, so pregnancy should be regarded as a period requiring individualized neurological and obstetric surveillance rather than assumed to be uniformly protective or harmful. ^[119] A separate UK cohort of approximately five million pregnancies evaluated adverse pregnancy outcomes across 17 autoimmune diseases, including MG, using linked primary-care and hospital data; this provides broader autoimmune-pregnancy context but is not a substitute for MG-specific exacerbation estimates. ^[125]

Older adults and late-onset MG

Late-onset MG is characterized in the cited literature by immunosenescence, comorbidity, increased risk of myasthenic crisis, and limitations on conventional immunosuppression. ^[92]C In a real-world study of refractory, acetylcholine-receptor-antibody-positive late-onset generalized MG, eculizumab was evaluated for clinical outcomes, safety, and quality of life; the supplied abstract identifies the population and objectives but does not provide numerical outcomes. ^[92]C A separate retrospective South Wales cohort evaluated early low-dose rituximab in non-thymomatous, immunosuppression-naïve, AChR-antibody-positive generalized MG within 12 months of generalization; participants received a single 500-mg infusion, and outcomes included MGFA class, activities of daily living, rescue therapy, prednisolone exposure, and adverse events. ^[114]C The cohort had 17 patients, with a median age of 71 years, limiting generalizability and requiring confirmation in larger studies. ^[114]C

Serologic and clinical treatment subgroups

The phase 3 ADAPT subgroup analysis examined efgartigimod in a broad AChR-antibody-positive generalized MG population receiving at least one stable MG treatment. ^[101] Efficacy was assessed using MG-ADL and QMG responder rates during treatment cycles 1 and 2, while treatment-emergent adverse events were evaluated across subgroups. ^[101] In VIVACITY-MG3, nipocalimab was studied in seropositive adults with generalized MG, including anti-AChR, anti-MuSK, and anti-LRP4 antibody-positive participants, at a 30-mg/kg loading dose followed by 15 mg/kg every 2 weeks for 24 weeks alongside standard care. ^[100] Prespecified outcomes included MG-QoL15r, Neuro-QoL Fatigue, EQ-5D-5L, and patient-reported fatigue severity and change. ^[100] Additional VIVACITY-MG3 analyses examined sustained MG-ADL and QMG responses over 24 weeks, using predefined meaningful and substantial improvement thresholds, including MG-ADL ≥2 or ≥3 points and QMG ≥3 or ≥4 points. ^[102]

Refractory disease and treatment sequencing

Real-world evidence has examined eculizumab after inadequate early response to efgartigimod. A prospective cohort enrolled 103 generalized MG patients treated with one efgartigimod cycle and subsequently included 18 patients with inadequate early response for evaluation of eculizumab. ^[111]C This evidence is observational and supports consideration of sequential complement inhibition only as an individualized strategy; it does not establish comparative efficacy. ^[111]C A predictive-model study sought to identify AChR-antibody-positive patients likely to achieve minimal symptom expression after low-dose rituximab using retrospective data and logistic regression. ^[115] Tacrolimus monotherapy was evaluated in 153 adults with mild-to-moderate, adult-onset MG; minimal symptom expression was the remission endpoint, and relapse predictors, safety, and cancer incidence were assessed. ^[123]C

Thymoma, thymectomy, and perioperative management

A retrospective study of 78 generalized MG patients undergoing thymectomy compared oral immunosuppression with rapid antibody-clearing therapy using lymphoplasmapheresis or efgartigimod. ^[94] Outcomes included postoperative QMG at 3 months, exacerbation at 1 month, MG-ADL and QMG through 6 months, operative measures, postoperative myasthenic crisis, and perioperative cost. ^[94] Long-term consequences of adult thymectomy were examined in a propensity-score-matched retrospective study comparing 425 thymectomy patients with cardiothoracic-procedure comparators, with follow-up to 10 years and outcomes including mortality, new malignancy, and autoimmune disease. ^[121] These studies address different questions—perioperative MG control versus long-term health outcomes—and should not be interpreted as interchangeable evidence. ^[94][121]

Immune checkpoint inhibitor–associated MG

MG–inflammatory myopathy overlap syndrome may occur as an immune-related adverse event after immune checkpoint inhibitor therapy, while a sporadic form, often associated with thymoma, also occurs without checkpoint inhibitor exposure. ^[118]C A multicenter retrospective cohort from eight Italian centers compared clinical features, antibody profiles, treatments, and outcomes of immune-checkpoint-inhibitor-related and sporadic overlap syndromes. ^[118]C Because the evidence is retrospective and concerns a rare overlap phenotype, recognition of concurrent myositis is essential when weakness, bulbar symptoms, respiratory involvement, or cardiac concerns arise during checkpoint inhibitor treatment. ^[118]C

Ocular-predominant presentations and diagnostic mimics

In patients presenting with diplopia, a prospective video-oculographic study evaluated repetitive horizontal and vertical saccades over 75 cycles to distinguish MG from unilateral third-, fourth-, or sixth-nerve palsy. ^[117] Prespecified measures included percentage change in saccadic range and time to target acquisition, with diagnostic performance assessed by ROC analysis. ^[117] These findings support objective fatigability testing as a potential adjunct when ocular MG and unilateral ocular motor cranial neuropathy are difficult to distinguish, but the study was diagnostic and cross-sectional rather than a treatment trial. ^[117]

Fatigue, sleep, comorbidity, and healthcare burden

General fatigue should be distinguished from neuromuscular fatigability. In a prospective observational study of clinically stable MG, depressive symptoms—but not obstructive sleep apnea severity—were associated with general fatigue; participants underwent validated fatigue, sleep, depression, symptom-severity, vigilance, and home sleep-apnea assessments. ^[112] MG is also associated with other autoimmune diseases: a Korean nationwide claims study evaluated autoimmune thyroid disease and other autoimmune conditions during the 10 years preceding MG diagnosis. ^[120] Hospital admissions, emergency-department visits, hospital days, and annual hospital costs were assessed in VIVACITY-MG3, including analysis of predictors of high-cost events in seropositive generalized MG. ^[116] Health-related quality-of-life outcomes and resource utilization should therefore be considered alongside clinical scale responses when evaluating treatment in medically complex patients. ^[100][116]

Safety considerations with targeted therapies

A TriNetX propensity-matched cohort compared C5-inhibitor-treated and untreated generalized MG patients, as well as ravulizumab versus eculizumab, with major adverse cardiovascular and thromboembolic outcomes as dedicated endpoints. ^[124]C The study reported an association between C5 inhibition and improved survival but increased cardiovascular risk; because it was retrospective and based on federated electronic-health-record data, the findings indicate a safety signal rather than proof of causation. ^[124]C Long-term IVIg effectiveness, safety, retreatment, and cost-effectiveness were evaluated in Japanese post-marketing surveillance across 316 facilities, although the cohort excluded patients who had not previously received corticosteroids or immunosuppressants. ^[95] Real-world efgartigimod research additionally assessed repeated treatment cycles, IgG reduction, MG-ADL, QMG, minimal symptom expression, steroid-sparing effects, and ocular, bulbar, limb, and trunk domains according to thymic status and concomitant treatment. ^[122]

Core management guidance

The principal international framework is the International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update, developed by an international expert panel using the RAND/UCLA appropriateness method and addressing seven treatment topics.^[136]D The Association of British Neurologists guideline aims to combine evidence-based recommendations with established best practice where evidence is limited and advises clinicians to seek specialist opinion when management choices cannot be resolved from evidence alone.^[132] The 2022 Japanese guideline revised MG diagnostic criteria, defined refractory MG, incorporated molecular-targeted therapies, divided MG into six clinical subtypes, and supplied treatment algorithms for MG and Lambert–Eaton myasthenic syndrome (LEMS).^[133] The 2025 Portuguese consensus guideline describes MG diagnosis as based on fatigable weakness, supported by neurophysiologic testing and/or detection of pathogenic antibodies, including antibodies against the acetylcholine receptor (AChR) and, less frequently, muscle-specific kinase (MuSK).^[127] Taiwan’s clinical practice guideline was developed by 37 MG specialists and a patient representative after literature review covering 2015–2024 and a modified Delphi process; it addresses diagnosis and treatment in the context of increasing generalized MG prevalence and healthcare utilization in Taiwan.^[131]

Diagnosis, crisis, and acute treatment

MG diagnosis should be integrated with the clinical finding of fatigable weakness, antibody testing, and neurophysiologic assessment rather than relying on a single test.^[127] The 2007 AAN evidence report on ocular MG systematically reviewed medical treatments for ocular disease, but that report is explicitly retired and should not be treated as a current standalone guideline.^[82] Earlier European guidance recommended anticholinesterase medication as initial MG treatment, with caution in MuSK-antibody disease, and recommended plasma exchange in severe disease or before surgery.^[84] The 2006 European guideline similarly placed anticholinesterase drugs first and considered plasma exchange a short-term treatment for severe MG and a preoperative intervention.^[85]

IVIG and plasma exchange are established short-term therapies for acute exacerbations and severe MG in the cited European neurological guidance; the EFNS IVIG guideline classified IVIG for acute MG exacerbations and short-term treatment of severe MG as a level A recommendation.^[87] A Canadian evidence-based guideline likewise addressed IVIG use across 22 neurologic conditions and was developed in response to substantial growth in IVIG utilization, including off-label use.^[88] A later review of IVIG guidance reiterates level A effectiveness for acute MG exacerbations and short-term treatment of severe MG.^[128]

Botulism is an important diagnostic and treatment-related differential because botulinum neurotoxin blocks acetylcholine release at the neuromuscular junction and causes potentially life-threatening flaccid descending paralysis beginning with cranial nerve palsies and possibly progressing to limb weakness and respiratory failure.^[79] The 2021 US botulism guideline describes foodborne, wound, infant, adult intestinal-colonization, and iatrogenic botulism, including illness after high-concentration cosmetic or therapeutic toxin injections.^[79]

Thymectomy and thymic disease

For patients younger than 65 years with nonthymomatous, AChR-antibody-positive generalized MG, the AAN practice advisory found that oral prednisone plus thymectomy produced better clinical outcomes than prednisone alone in a Class I study, including a greater probability of achieving minimal-manifestation status.^[83] This recommendation applies specifically to the studied AChR-positive generalized population and should not automatically be extrapolated to MuSK-positive disease, purely ocular MG, or thymoma-associated MG.^[83]

Thymoma is associated with autoimmune paraneoplastic diseases such as MG, whereas these disorders typically do not occur with thymic carcinoma.^[80] The NCCN guideline recommends diagnosis, treatment, and surveillance planning for thymomas and thymic carcinomas through a multidisciplinary team experienced in these uncommon mediastinal tumors.^[80] In suspected paraneoplastic neurologic disease, the EFNS task force recommends tumor screening as soon as possible because the neurologic syndrome often precedes malignancy detection and the tumor affects prognosis and treatment; thymoma is among the malignancies considered in relation to MG.^[86]

Treatment goals, outcomes, and refractory disease

International consensus-based care commonly uses MGFA post-intervention status, with minimal manifestations or better serving as an important treatment goal.^{[129][134][135]} In a large Japanese analysis, investigators evaluated clinical metrics intended to reduce ambiguity in assigning minimal-manifestation status, using 3,800 MG patients overall and 2,784 patients with generalized MG.^[134] A Duke MG Clinic retrospective cohort followed patients for at least 2 years and analyzed outcomes under International Consensus Guidance-based care, including time to treatment goals and post-intervention status.^[129] Comorbid diseases may influence clinical outcomes, and one observational study evaluated comorbidity patterns across six MG subgroups defined by antibodies, age at onset, and thymoma status.^[135] The Japanese revision specifically defines refractory MG and includes molecular-targeted drugs in its treatment framework.^[133] A 2024 retrospective study of 116 patients assessed serial antibody-concentration ratios as a possible marker of treatment-refractory MG, using International Consensus Guidance criteria as the reference standard; this remains observational diagnostic research rather than a treatment guideline.^[130]

Special circumstances and resource links

During the COVID-19 outbreak, French neuromuscular-network guidance recommended reserving hospitalization for emergencies, nondeferrable treatment, evaluations whose delay could compromise survival, and cardiorespiratory assessments for which delay might be harmful.^[126] This pandemic-specific document is a contingency resource rather than a general MG treatment standard.^[126]

Clinicians should therefore use current consensus and national guidelines for routine management, apply disease subtype and antibody status when interpreting recommendations, involve experienced multidisciplinary teams for thymic disease, and use IVIG or plasma exchange for appropriately selected severe or exacerbated cases.^{[80][83][87][127][132][136]D}